GC-MS-Based Quantification and Chemometric Discrimination of Multi-Marker Profiles in Carthami Flos-Based Pharmacopuncture Formulations Authors: Won-Young Cho, Hyundu Roh, Jiyeon Gong, Kyung Hoon Lee, Byung Soo Ahn, Daeyong Kim, Tae Han Yook, Gabsik Yang, Wonwoong Lee Published: 2026 ABSTRACT AbstractObjectivesPharmacopuncture is widely used in traditional Korean medicine, but its clinical reliability depends on chemical consistency and quality assessment. The present study aimed to establish a quantitative approach using gas chromatography-mass spectrometry (GC-MS) for simultaneously identifying and profiling key fatty acid marker compounds in Carthami Flos (CF) and Carthami Flos combined with deer antler (CFC) formulations. Whether this approach could be used in comparative quality evaluation was also evaluated.MethodsThe GC-MS method was used to quantify four fatty acids (palmitic acid, stearic acid, oleic acid, and linoleic acid) in CF and CFC formulations. Analytes were identified based on retention times and characteristic electrospray ionization mass spectral fragment ions. The analysis was conducted in the selective ion monitoring (SIM) mode to enhance analytical selectivity and sensitivity, particularly for structurally similar fatty acids. Univariate analysis and principal component analysis (PCA) were performed.ResultsAll four fatty acids were consistently detected and unambiguously identified in both CF and CFC formulations under the optimized GC-MS conditions. The SIM mode enabled the selective differentiation and accurate quantification of structurally similar fatty acids. Linoleic acid was the most abundant component in both formulations. Univariate analysis revealed a significant difference only in oleic acid content, but PCA discriminated CF and CFC samples, with the first two principal components explaining 97.56% of the total variance.ConclusionThe GC-MS-based multi-marker profiling seems feasible for quantitative comparison and PCA-based discrimination of CF and CFC pharmacopuncture formulations.Keywords: carthami flos, fatty acids, gas chromatography-mass spectrometry, multi-marker profiling, pharmacopuncture INTRODUCTION Pharmacopuncture (herbal acupuncture), known as yakchim in Korean, is a therapeutic modality in traditional Korean medicine that involves the injection of herbal extracts into specific acupuncture points [1-3]. By integrating the principles of acupuncture and herbal pharmacotherapy, it provides both localized and systemic therapeutic effects [4, 5]. Because pharmacopuncture has demonstrated clinical efficacy in musculoskeletal disorders, circulatory dysfunction, and immune modulation, it has become a major component of integrative medical practice in East Asia [6-8]. The efficacy and safety of herbal preparations depend on consistent chemical composition. However, natural product-based formulations often vary due to differences in geographical origin, cultivation conditions, and harvest time [9]. This variability can affect therapeutic activity, reproducibility, and safety, limiting the standardization and broader acceptance of traditional remedies. Therefore, rigorous quality control and standardization, supported by appropriate analytical methods, are essential to ensure the reproducibility and scientific credibility of pharmacopuncture products [10]. Among these formulations, Carthami Flos-based pharmacopuncture products, including Carthami Flos (CF) from safflower (Carthamus tinctorius) and Carthami Flos combined with deer antler (Cervi Pantotrichum Cornu) (CFC), are widely used in clinical practice [11]. Safflower has anti-inflammatory, analgesic, antioxidant, and lipid-modulating effects and has long been used to relieve pain and improve circulation [12-17]. Deer antler has traditionally been used as a vitality-enhancing tonic in East Asian medicine and has shown immunomodulatory, anti-inflammatory, anti-fatigue, and bone-supporting effects [18-24]. In CFC formulations, these ingredients are used together for musculoskeletal and circulatory disorders. However, the chemical complexity of the combined formulation makes objective compositional profiling and quantitative evaluation challenging. Gas chromatography-mass spectrometry (GC-MS) is widely used to identify and quantify volatile and semi-volatile compounds in complex natural product matrixes [25, 26]. Its high sensitivity and selectivity make it especially suitable for lipid-based samples and volatile metabolites [27, 28]. For pharmacopuncture formulations, GC-MS profiling can provide useful compositional information for comparative evaluation and marker-based analysis. In this study, we used a GC-MS-based multi-marker profiling strategy to identify and quantify four major fatty acid markers—palmitic acid, stearic acid, oleic acid, and linoleic acid—in CF and CFC pharmacopuncture formulations. We then combined targeted quantification with principal component analysis (PCA) to compare their compositions and characterize formulation differences. MATERIALS AND METHODS 1. Chemicals and materials Palmitic acid, stearic acid, oleic acid, and linoleic acid were used as marker compounds for CF and CFC pharmacopuncture formulations. Phenanthrene-d10 was used as an internal standard (IS) for quantitative analysis. All analytical standards were purchased from Sigma Aldrich (St. Louis, MO, USA). Analytical grade ethyl acetate (EA) was obtained from J.T. Baker (Phillipsburg, NJ, USA). All reagents and solvents used in this study were of analytical grade or higher purity. Deionized water was prepared using an Evo CB purification system (Mirae ST, Anyang, Republic of Korea). CF and CFC pharmacopuncture products were obtained from AJBIO Co., Ltd (Gyeongsan, Republic of Korea) and were manufactured as a single production lot under controlled conditions. The CFC formulation consisted of Carthami Flos oil (0.2 g/mL) and deer antler extract (0.012 g/mL). 2. Sample preparation Individual chemical authentic standards were weighed and dissolved in EA at 1,000 μg/mL to prepare stock solutions. The working solution comprised aliquots of the stock solutions that were serially diluted with EA to obtain calibration standards. Before analysis, the IS phenanthrene-d10 (100 μg/mL) was added (20 μL) to each calibration standard and sample. The peak area ratio of each analyte relative to the IS was quantified. CF and CFC pharmacopuncture samples were diluted with EA to fall within the calibration range, filtered through 0.22-μm polytetrafluoroethylene syringe filters, and transferred to GC vials for analysis. All analytical samples (n = 5 per formulation) were analyzed separately as independently prepared samples from the same manufacturing lot to assess within-lot compositional consistency. 3. GC-MS conditions GC-MS analysis was performed using an Agilent 6890N gas chromatograph coupled to an Agilent 5975C mass spectrometer (Palo Alto, CA, USA) operating in electrospray ionization (EI) mode at 70 eV. Chromatographic separation was performed on a ZB-50 capillary column (30.0 m × 0.25 mm i.d., 0.25 μm film thickness; Phenomenex, Torrance, CA, USA). Helium (99.999%) was used as the carrier gas at 1.0 mL/min. The injector temperature was 280℃ with a 10:1 split ratio. The oven temperature program was as follows: initial 40℃ for 3 min; ramp to 150℃ at 15℃/min (hold 1 min); final ramp to 310℃ at 25℃/min (hold 3 min). The MS transfer line and ion source temperatures were set at 280℃ and 230℃, respectively. Data were acquired in full scan and selected ion monitoring (SIM) modes. For SIM acquisition, time-segmented windows and characteristic ions were selected to achieve sensitive and selective detection of the four marker compounds in CF and CFC formulations. The monitored ions (m/z) were set as follows: 14.00-14.70 min (palmitic acid), m/z 60, 73, and 256; 14.70-15.00 min (phenanthrene-d10, IS), m/z 188; 15.00-15.61 min (stearic acid and oleic acid), m/z 73, 129, 284 and m/z 55, 69, 282, respectively; and 15.61-41.00 min (linoleic acid), m/z 67, 81, and 280. For each analyte, the specific and abundant fragment ion was designated as the quantifier ion (palmitic acid, m/z 256; stearic acid, m/z 284; oleic acid, m/z 282; linoleic acid, m/z 280). Secondary characteristic ions were used as qualifier ions. Ion ratios were monitored and confirmed to remain within ±20% of those obtained from authentic standards. Dwell times were automatically assigned by the instrument software to ensure sufficient data points across each chromatographic peak. Compound identification was confirmed by matching retention times and SIM ion responses with those of authentic standards analyzed under identical conditions. 4. Quantification of the four marker compounds For the quantitative determination of the four marker compounds (palmitic acid, stearic acid, oleic acid, and linoleic acid), the limit of detection (LOD, S/N = 3.3), limit of quantitation (LOQ, S/N = 10), and linearity within the calibration range were evaluated. Calibration curves were constructed over the concentration range of 100-1,000 μg/mL for all analytes. The concentrations of most marker compounds in CF and CFC samples fell within the established calibration range. However, the concentration of linoleic acid fell beyond this range. Accordingly, CF and CFC samples were appropriately diluted with EA to ensure that linoleic acid concentrations were within the established calibration range before analysis. All reported concentrations were calculated by applying the corresponding dilution factors to these measured values. RESULTS 1. Identification of marker compounds To identify marker compounds in CF and CFC samples, we examined all peaks in the total ion chromatograms under optimized GC-MS conditions. Preliminary full scan profiling revealed several major lipid constituents in both formulations. Library matching and peak area comparisons showed that four fatty acids—palmitic acid, stearic acid, oleic acid, and linoleic acid—were among the most abundant and consistently detected compounds in both samples (Fig. 1). Because CF-based pharmacopuncture formulations are oil-based matrixes derived from safflower, these fatty acids are structurally relevant and chemically stable, making them suitable for quantitative evaluation. We therefore selected them as marker compounds for subsequent quantitative and comparative analyses. Total ion chromatograms (TICs) of (A) CF and (B) CFC pharmacopuncture formulations. Peaks were identified as follows: 1, Palmitic acid; 2, Stearic acid; 3, Oleic acid; 4, Linoleic acid; IS, Phenanthrene-d10. Compound identification was confirmed by comparing retention times and EI mass spectral fragmentation patterns with those of authentic standards (Fig. 2). Under EI conditions (70 eV), each compound showed characteristic molecular-related ions: m/z 256 for palmitic acid, m/z 284 for stearic acid, m/z 282 for oleic acid, and m/z 280 for linoleic acid. These diagnostic ions enabled unambiguous identification of the marker compounds in the complex sample matrix. Electrospray ionization mass spectra of authentic standards for (A) palmitic acid, (B) stearic acid, (C) oleic acid, and (D) linoleic acid. These spectra formed the basis for confirming the compound identification in CF and CFC formulations. 2. Establishment of GC-MS conditions The optimized GC-MS conditions enabled reproducible detection of all four marker compounds. In full scan mode, oleic acid and stearic acid partially overlapped chromatographically because they have the same carbon chain length (C18) and similar physicochemical properties. To resolve this limitation, we used SIM mode with compound-specific diagnostic ions (Fig. 3). Selected ion monitoring (SIM) chromatograms of four marker compounds in (A) CF and (B) CFC pharmacopuncture formulations. (Peaks were identified as follows: 1, Palmitic acid; 2, Stearic acid; 3, Oleic acid; 4, Linoleic acid; IS, Phenanthrene-d10). SIM acquisition markedly improved analytical selectivity and sensitivity, allowing reliable differentiation and quantification of structurally similar analytes despite partial co-elution. Under these optimized conditions, retention times remained stable and peak shapes were symmetrical across replicate injections, supporting the analytical stability of the profiling approach. 3. Quantitative analysis of marker compounds in CF and CFC samples We quantified the four marker compounds in CF and CFC samples using calibration curves constructed from authentic standards. All curves showed excellent linearity across the calibration range, with determination coefficients (R2) greater than 0.990. The LODs and LOQs ranged from 5-12 and 16-37 μg/mL, respectively. Using the established GC-MS conditions, all four marker compounds were successfully quantified in both formulations (Table 1). In both CF and CFC, linoleic acid was the most abundant component, followed by oleic acid, stearic acid, and palmitic acid. Statistical analysis was then performed to distinguish the two preparations. Among the four analytes, only oleic acid showed a significant difference between CF and CFC (p = 0.0079), whereas palmitic acid, stearic acid, and linoleic acid did not (p > 0.05). Table 1Quantitative determination of four fatty acid marker compounds in CF and CFC pharmacopuncture formulationsAnalytesCalibration range (μg/mL)Linear regression equationR2LODs (μg/mL)LOQs (μg/mL)Precision and accuracy (%)*Concentrations (μg/mL)** CFCFCPalmitic acid100-1,000y = 0.0125x + 0.13930.990113298.16 ± 6.70127.31 ± 13.02111.44 ± 6.63Stearic acid100-1,000y = 0.0032x – 0.09050.995516100.08 ± 7.78178.22 ± 6.91182.82 ± 6.15Oleic acid100-1,000y = 0.0007x – 0.02860.991123685.85 ± 0.46319.79 ± 25.07410.90 ± 36.57Linoleic acid100-1,000y = 0.0106x – 0.27740.994123799.00 ± 8.481,038.28 ± 50.361,023.05 ± 32.65*Intra-day precision and accuracy results were determined at 500 μg/mL.**Values are expressed as the mean ± standard deviation (SD) (n = 5). Quantitative determination of four fatty acid marker compounds in CF and CFC pharmacopuncture formulations *Intra-day precision and accuracy results were determined at 500 μg/mL. **Values are expressed as the mean ± standard deviation (SD) (n = 5). 4. PCA-based discrimination of CF and CFC To further assess the discriminatory power of the selected marker compounds, we performed principal component analysis (PCA) using the quantitative data for all four analytes. The PCA score plot showed clear separation between CF and CFC samples (Fig. 4). Because all samples came from a single manufacturing lot for each formulation, this separation reflects formulation-dependent compositional differences rather than batch-to-batch variability. The first principal component (PC1) explained 64.69% of the total variance, and the second principal component (PC2) explained 32.87%, giving a cumulative variance of 97.56%. The distinct clustering indicates that differences in the relative levels of the four marker compounds are sufficient to distinguish CF from CFC despite their overall compositional similarity. Principal component analysis (PCA) score plot based on the quantitative levels of four marker compounds in CF and CFC pharmacopuncture formulations. Each point represents an independent aliquot (technical replicate, n = 5 per formulation) prepared from the same manufacturing lot. Numbers were identified as CF (1-5) and CFC (6-10). DISCUSSION Although CF-based pharmacopuncture preparations, including CF and CFC, are widely used in traditional Korean medicine to treat various symptoms, their active constituents and reliable quality control markers remain insufficiently characterized. This lack of chemical standardization has limited both mechanistic understanding and objective quality evaluation. In this study, we proposed four fatty acids—palmitic acid, stearic acid, oleic acid, and linoleic acid—as practical markers for quantitative comparison and compositional evaluation of CF and CFC formulations. These compounds are major constituents and provide useful indicators of raw material composition and within-lot consistency. Although oleic acid and stearic acid showed partial co-elution under conventional chromatographic conditions, SIM mode enabled selective and accurate quantification through compound-specific fragment ions. This mass spectrometric selectivity compensated for the chromatographic limitations of structurally similar long-chain fatty acids and supported reliable quantitative comparison. Importantly, PCA of the quantitative marker data added a chemometric dimension to quality assessment. Although only oleic acid showed a statistically significant difference in the univariate analysis, multivariate PCA clearly distinguished CF from CFC. This separation may reflect differences in relative fatty acid composition introduced by the addition of deer antler, which contains palmitic acid, stearic acid, oleic acid, and linoleic acid [29]. The high cumulative variance explained by PC1 and PC2 (97.56%) further indicates that the selected marker compounds captured the key compositional differences between CF and CFC. These results highlight the value of combining targeted quantitative analysis with multivariate statistical tools for quality control. Although single-marker evaluation may be insufficient to distinguish complex herbal formulations, a multi-marker approach combined with PCA enables sensitive discrimination and objective classification. Overall, the GC-MS-based multi-marker profiling approach presented in this study provides a practical framework for quantitative comparison and PCA-based discrimination of CF and CFC pharmacopuncture preparations. By combining targeted marker quantification with principal component analysis, this strategy enables objective compositional characterization within a single manufacturing lot. Future studies using multiple independent batches will be needed to assess inter-batch variability. CONCLUSION This study established a GC-MS-based multi-marker profiling approach for CF and CFC pharmacopuncture formulations using four fatty acid markers: palmitic acid, stearic acid, oleic acid, and linoleic acid. Combined targeted quantification and PCA effectively distinguished the two formulations, supporting the use of these fatty acids as practical chemical markers. This approach provides a useful framework for quantitative comparison and compositional characterization within a single manufacturing lot. Footnotes AUTHORS’ CONTRIBUTIONS Won-Young Cho: Investigation, Writing. Hyundu Roh: Validation, Software. Kyung Hoon Lee: Investigation, Resources. Byung Soo Ahn: Investigation, Resources. Tae Han Yook: Review & Editing. Gabsik Yang: Review & Editing. Wonwoong Lee: Supervision, Review & Editing. ETHICAL APPROVAL No ethical approval was required as this study did not involve human participants or laboratory animals. DATA AVAILABILITY The authors state that all information provided in this article can be obtained from the corresponding author upon request. CONFLICTS OF INTEREST All authors declare no conflicts of interest in this work. FUNDING This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean Government (MSIT) (RS-2021-NR061340) and the Regional Innovation System & Education (RISE) program through the Jeonbuk RISE Center, funded by the Ministry of Education (MOE) and the Jeonbuk State, Republic of Korea (2025-RISE-13-WSU). REFERENCES